CXCL11 and B cell marker B220 positively correlated with a better clinical outcome of breast cancer, suggesting tumor-associated neutrophils can suppress CD8+ T cells by blocking another protective immune branch acting around the tumor sites. Here, CD8A is linked to neoplasm.